Neurocrine Biosciences | 营业费用



金融业
股票价格
USD
资产
USD 4.27B
现金及等价物
USD 340.2M
销售成本
USD 264M
流动资产
USD 2.16B
流动负债
USD 638M
债务
USD 439.1M
EBIT
USD 239.3M
EBITDA
USD 246.7M
员工
1.8K
EPS每股收益
USD 2.17
股本和储备
USD 3B
销售毛利
USD 780.9M
债务利息支出
USD 1.1M
贷款资金
USD 169.5M
市值
USD 13.89B
净收入
USD 209.5M
营业费用
USD 555.6M
营业利润
USD 239.3M
普通股股本
USD 99.7M
PE价格收益
USD 33.27
税前利润
USD 291.8M
销售收入
USD 794.9M
销售和管理费用
USD 291.6M
股票
USD 69.3M
贸易债权人
USD 119.9M
应收帐款人
USD 728M


营业费用 更改 日
AbbVie USD 10.81B 13.45B 2025-12
Acadia Pharmaceuticals USD 242.88M 10.68M 2025-09
Agios Pharmaceuticals USD 129.75M 9.76M 2025-09
ALKERMES USD 1.73B 1.44B 2025-09
Alnylam Pharmaceuticals USD 881.04M 91.16M 2025-09
Amgen USD 5.9B 773M 2025-12
Biogen USD 1.88B 81.4M 2025-09
BioMarin Pharmaceutical USD 807.82M 259.3M 2025-09
Cytokinetics USD 168.69M 9.58M 2025-09
Dynavax Technologies USD 73.6M 7.41M 2025-09
Enanta Pharmaceuticals USD 79.28M 14.26M 2025-06
Exelixis USD 362.75M 21.35M 2025-12
Gilead Sciences USD 4.96B 707M 2025-12
Halozyme Therapeutics USD 136.34M 13.06M 2025-09
Incyte USD 1.12B 3.53B 2025-12
Ionis Pharmaceuticals USD 316.9M 4.69M 2025-09
Nektar Therapeutics USD 85.09M 109.3M 2025-09
Neurocrine Biosciences USD 555.6M 13.7M 2025-09
Pfizer USD 12.91B 79.89B 2025-12
Prothena USD 42.18M 14.25M 2025-09
Regeneron Pharmaceuticals USD 2.99B 27.97B 2025-12
Repligen USD 176.13M 279K 2025-09
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sarepta Therapeutics USD 462.23M 33.28M 2025-09
Teva Pharmaceutical Industries USD 4.22B 812M 2025-12
Ultragenyx Pharmaceutical USD 330.82M 56.44M 2025-09
Vertex Pharmaceuticals USD 1.84B 27.1M 2025-09
Xoma USD 22.84M 1.67M 2024-09


Neurocrine Biosciences 营业费用 - 当前值，历史数据，预测，统计，图表和经济日历 - Feb 2026.